{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:11:16Z","timestamp":1760987476272,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Assistance Publique-H\u00f4pitaux de Paris Clinical Research and Development Department"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.semarthrit.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T02:03:34Z","timestamp":1537149814000},"page":"1014-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"48","author":[{"given":"Brigitte","family":"Bader-Meunier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Krzysiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ir\u00e8ne","family":"Lemelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pajot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lia","family":"Carbasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvaine","family":"Poignant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-333X","authenticated-orcid":false,"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Choupeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salima","family":"Hacein-Bey-Abina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saik","family":"Urien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.09.002_bib0001","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.23493","article-title":"Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0004","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","article-title":"Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0008","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0009","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","article-title":"Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score","volume":"73","author":"Consolaro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0011","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0013","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.autrev.2015.05.001","article-title":"New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis","volume":"9","author":"Meroni","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"Van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket490","article-title":"German BIKER registry collaborative study group predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis","volume":"53","author":"Geikowski","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2018.09.002_bib0016","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kev434","article-title":"Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British society for paediatric and adolescent rheumatology etanercept cohort study","volume":"55","author":"Kearsley-Fleet","year":"2016","journal-title":"Rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017218302853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:58:02Z","timestamp":1758733082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017218302853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0049017218302853"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.09.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}